This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2001, I was at Millennium Pharmaceuticals, one of the major players in the nascent field of genomics drug discovery, and that time has strong parallels to the changing state of drug development today. In fact, the Millennium of 2001 (pre-Takeda acquisition) had one drug approved which was Velcade (bortezomib).
Dr Rochlin earned a PhD in MolecularBiology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania. Science 294(5542):605-609 (2001). and MBA students with real-world consulting experiences. J Hemotother 5(5):503-9 (1996).
Advances in molecularbiology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens.
He also posited the existence of a physical material to explain inheritance, which he called “elementen,” or “elements,” many years before nucleic acid had even been isolated 4 and more than 80 years before British biologists unveiled DNA’s structure and founded the field of molecularbiology.
I’ve chosen these two because I think they are the linchpin by which we’ll be able to build broadly useful AI models for cell and molecularbiology. But looking ahead to the second bottleneck, what does it mean to say that biology is “complex”? The cost of sequencing a human genome.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content